Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05977673
Title Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy: a Phase II, Open-label Study (FIL_Tisle-HL)
Acronym FIL_Tisle-HL
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fondazione Italiana Linfomi - ETS
Age Groups: senior | adult
Covered Countries ITA

No variant requirements are available.